The integrin α6β4 is a laminin receptor that associates with aggressive behavior in many cancers, though its significance in gliomas has not been established. Mutations in isocitrate dehydrogenase 1 and 2 (IDH mut ) are common in gliomas, especially 1p/19q co-deleted oligodendrogliomas, and correlate with improved patient survival. We sought to determine whether there is a link between integrin β4 and malignant behavior in gliomas. An inverse relationship was identified between IDH mut and integrin β4 expression in a glioma TMA (P < 0.0001) and in TCGA grade II-IV gliomas (P < 0.0001). Methylation of CpG sites in the ITGB4 promoter is significantly higher in IDH mut gliomas when compared to wild-type tumors, and both ITGB4 methylation and reduced ITGB4 mRNA are not only most prominent in the 1p/19q codeleted subset of IDH mut tumors, but fully account for the lower ITGB4 expression observed in IDH mut gliomas. In fact, ITGB4 is one of the most downregulated genes in IDH mut 1p/19q codeleted gliomas compared to IDH mut 1p/19q intact gliomas (P = 3.2x10 -39 ). In patient-derived glioma cells, we found that integrin β4 is enriched in the stem-like population, and that knockdown of integrin β4 slows glioma growth in vitro (P < 0.001) and in vivo (P = 0.01). Lower ITGB4 mRNA levels were also associated with longer overall survival in multiple patient cohorts (P = 0.0005; P < 0.0001). These data suggest that integrin β4 increases glioma malignancy, and that its relative paucity may contribute to the better prognosis in IDH1/2 mutant, 1p/19q codeleted oligodendrogliomas.
Introduction
Gliomas account for 30% of all primary tumors of the central nervous system (CNS) and represent about 80% of malignant CNS tumors (13) . Glioblastoma multiforme (GBM) accounts for over 50% of gliomas and carries an extremely poor prognosis, with a median survival of around 14 months even when treating with temozolomide and radiation therapy (57) . A key reason for this dismal prognosis is the diffusely infiltrative nature of these tumors, rendering complete surgical excision impossible. Diffuse low and intermediate-grade gliomas have variable outcomes that depend on the underlying genomic alterations present in the tumor, with median survival ranging from 1 to over 12 years (8) .
Mutations in isocitrate dehydrogenases types 1 and 2 (IDH1/2) are present in the majority of World Health Organization (WHO) grade II and III gliomas, and are also characteristic of secondary GBMs (21, 26, 46, 61) . Both enzymes normally oxidize isocitrate to α-ketoglutarate, but point mutations at R132 in IDH1 or R172 in IDH2 produce neoenzymatic activity, reducing α-ketoglutarate to D-2-hydroxyglutarate (D2HG) (12, 60) . D2HG may contribute to gliomagenesis by promoting global DNA and histone hypermethylation and suppressing cellular differentiation (37). Yet these mutations are powerful favorable prognostic markers, as tumors with mutant IDH1 or IDH2 (henceforth referred to as "IDH mut ") tend to be much less aggressive compared to their wildtype counterparts (24) . However, IDH mut gliomas that also contain 1p/19q co-deletion have an even better prognosis compared to IDH mut gliomas lacking 1p/19q co-deletion: in an analysis of 654 grade II-IV gliomas from The Cancer Genome Atlas (TCGA), the median survival of IDH mut , 1p/19q co-deleted gliomas was 134.3 months, compared to 87.5 months for IDH mut , 1p/19q intact gliomas and 14.9 months for IDH1 wt gliomas (Supplemental Figure 1 ; P < 0.0001). The reasons for this survival difference between the major subsets of IDH mut gliomas is incompletely understood.
Integrins are extracellular matrix receptors that regulate a number of diverse cellular processes including survival, motility, angiogenesis and proliferation (19, 41, 58) . In addition to their normal functions, integrins can also promote tumor initiation and progression, in part through their ability to enhance receptor tyrosine kinase activity and stimulate proliferative signaling (19) . These effects are particularly notable for the integrin α6β4, as it promotes invasion by altering immediate downstream signaling to phosphatidylinositol 3-kinase (PI3K), AKT, MAPK and the Rho small GTPases (19, 36, 42, 43, 53) . The integrin α6β4 is comprised of an α and a β subunit that, combined, give the integrin specificity for various laminins. The integrin β4 subunit (referred to herein as integrin β4) has a long cytoplasmic signaling domain that contributes to its ability to promote invasion and metastasis (55) . The integrin β4 has also been shown to regulate the expression of genes involved in cell motility, invasion and the metastatic cascade (9) . Overexpression of the integrin β4 has been observed in a variety of neoplasms where it is associated with aggressive biology, invasiveness, and poor prognosis (6, 27, 38, 55, 56) . Furthermore, integrins facilitate stem cell properties in a number of human malignancies (52) , including integrin α6, also known as CD49f, which is the binding partner for integrin β4.
The contribution of integrin β4 to carcinoma progression has been the subject of extensive research in other cancer types; however, expression and function of the integrin β4 has not been studied thoroughly in gliomas. It is not known whether integrin β4 expression is regulated by driver mutations such as in IDH1/2, or whether expression of the integrin β4 is influenced by recurrent cytogenetic abnormalities such as 1p/19q co-deletion. As the integrin β4 is known to promote proliferation in other neoplasms, we sought to determine whether integrin β4 contributes to tumor growth and self-renewal in gliomas, and whether differential regulation of ITGB4 could be responsible for the improved prognosis observed in the IDH mut , 1p/19q codeleted subset. We also sought to determine whether integrin β4 is associated with clinicopathologic variables such as tumor grade and patient survival. Our findings may help explain why IDH mut , 1p/19q co-deleted gliomas are even less aggressive than IDH mut gliomas with intact 1p/19q.
Materials and Methods:

Tissue Microarray Construction
Formalin-fixed, paraffin-embedded (FFPE) glioma tissues were retrieved from the pathology archives at the University of Kentucky. Deidentified tissue microarrays (TMAs) were constructed from the gliomas as previously described (17) . A total of 104 cases comprised the TMAs, including 9 nonneoplastic controls (cortical dysplasia), 9 grade II astrocytomas, 11 grade III astrocytomas, 12 anaplastic oligodendrogliomas, 16 grade II oligodendrogliomas, and 47 grade IV GBMs. Treatment and outcomes were obtained via the Kentucky Cancer Registry.
Institutional Review Board approval was obtained prior to collecting the archival tissues for TMA construction and patient survival data.
Immunohistochemistry
Glioma TMA sections (4 μm) were stained using a rat monoclonal primary antibody to the integrin β4 subunit (CD104; clone 439-9B; BD Pharmingen, San Jose, CA) at a concentration of 5μg/ml according to a previously described protocol (11) . Integrin β4 expression was scored using a semiquantitative scale as follows: negative (0), minimal staining (1), weakly positive (2), moderately positive (3), strongly and diffusely positive (4) . Endothelial cells were used as internal positive controls while non-neoplastic tissue cores served as negative controls. Scoring was done while blinded to WHO grade, IDH mut status, and other clinicopathological variables.
Results from each of three tissue cores were averaged together to produce a final score for each tumor.
R132H IDH1 immunohistochemistry of TMAs was performed as previously described (17) .
Of note, 5 TMA cases were immunonegative for R132H IDH1 but were clinically suspected of having a less common IDH1 or IDH2 mutation based on mutation-associated variables like WHO grade and younger patient age. Of those 5, a single anaplastic astrocytoma turned out to have R132S IDH1 via pyrosequencing, as per standard clinical workup of gliomas.
Cell culture
The LN18 (CRL-2610) glioma cell line was purchased directly from ATCC and was cultured in RPMI 1640, 10% fetal bovine serum, and 1% penicillin streptomycin, purchased from Life Technologies (Carlsbad, CA). Cells were cultured in humidified conditions at 37°C and 5% CO2.
Cancer stem cell (CSC) derivation and xenograft maintenance
Established patient-derived GBM xenografts were previously reported (3, 20, 51) and were obtained via a material transfer agreement from Duke University (T4121) or the Mayo Clinic (GBM10). Xenografts were originally established under IRB-approved protocols in a deidentified manner using excess tissue taken from consented patients. For experimental studies, GBM cells were dissociated from established xenografts under Cleveland Clinic-approved Institutional Animal Care and Use Committee protocols as described (1) . Xenografts were passaged in immune-deficient NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice (obtained from The Jackson Laboratory, Bar Harbor, ME, USA). Freshly dissociated human GBM cells were unilaterally injected into the flank of 6-week-old female mice, and animals were sacrificed by CO2 asphyxiation and secondary cervical dislocation when the tumor volume exceeded 5% of the animal's body weight.
Tumor dissociation and GBM cell culture
Xenografted tumors were dissected and mechanically dissociated using a papain dissociation kit (Worthington Biochemical Corporation, Lakewood, NJ, USA) as previously described (1, 2, 20, 23, 31, 44) . After dissociation, cells were cultured overnight in Neurobasal medium (Life Technologies, Carlsbad, CA, USA) supplemented with B27 (Life Technologies), 1% penicillin/streptomycin (Life Technologies), 1 mM sodium pyruvate, 2 mM L-glutamine, 20 ng/mL EGF (R&D Systems, Minneapolis, MN, USA,), and 20 ng/mL FGF-2 (R&D Systems) in a humidified incubator with 5% CO2.
Self-renewal of integrin β4-high and -low populations using flow cytometry
After dissociation and overnight culture of cells isolated from xenografts, fluorescenceactivated cell sorting (FACS) was used to isolate cells based on surface levels of integrin β4 as described for other cell surface receptors (1, 20, 31) . Approximately 1x10 6 cells were filtered through a 70-µm cell strainer, centrifuged, and resuspended in 200 µl of FACS buffer (5% BSA in unsupplemented Neurobasal medium). Two microliters of mouse anti-integrin β4 (Abcam clone M126, ab29042) conjugated to PE/Cy7 (Abcam PE/Cy7® Conjugation Kit, ab102903) was added and incubated for 1 hour in the dark. Cells were then washed three times in unsupplemented Neurobasal medium and resuspended in 500 µl Neurobasal complete. Using DAPI as a control for live cells and an isotype control for signal specificity, the 20% of cells with the highest and 20% of cells with the lowest expression of integrin β4 were plated using a BD FACSAria II at increasing cell concentrations (1, 5, 10, and 20 cells/well) in 96-well plates. After 14 days, the number of wells containing spheres larger than 10 cells across was counted, and the stem cell frequency was calculated using the Walter and Eliza Hall Institute Bioinformatics Division ELDA analyzer (http://bioinf.wehi.edu.au/software/elda/) (25) .
Immunoblotting
Cells were harvested and lysed in RIPA buffer (150 mM NaCl, 0.5 mM EGTA, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mM Tris-HCl pH 7.4, 15 µg/ml protease inhibitor cocktail, 1 mM PMSF, 50 mM NaF and 10 mM sodium pyrophosphate). Total cell lysates (80 μg) were subjected to 8% SDS-PAGE, transferred and immunoblotted with mouse anti-CD104 (integrin β4, BD Bioscience) antibody; β-actin antibodies (Sigma-Aldrich) were used as the loading controls. Data are representative of at least three experiments.
Quantitative real time PCR (Q-PCR)
Total RNA was extracted using TRizol reagent (Life Technologies/ThermoFisher, Grand Island, NY). Total RNA (1μg) was used to reverse-transcribe into cDNA using the High Capacity 
ITGB4 knockdown by shRNA and Xenograft experiments
Patient derived primary GBM stem cells were obtained and isolated as described above.
Cells were labeled with CD133 antibody conjugated with APC and sorted to enrich for CD133+ stem cells using FACS. The CD133+ cells were then cultured in Neurobasal Media supplemented with B27 without vitamin A (Invitrogen), 10 ng/mL bFGF (Life Technologies, PHG0026), and 10 ng/mL EGF (Life Technologies, PHG0313). For stable knockdown of ITGB4 in CD133+ primary GBM stem cells, lentivirus was produced and cells were infected as described previously (54) . The cells were then placed under the selection of puromycin. The knockdown efficiency of ITGB4 was assessed by immunoblotting and Q-PCR. Intracranial tumor implantation was performed by injecting 10 µL (10 5 cells) into the right cerebral cortex of 5-
week-old female NU/J nude mice as previously described (3). Survival was tracked after tumor implantation. Any mouse showing distress, neurological signs (lethargy, hemiparesis, ataxia, seizures) or weight loss of greater than 10% was euthanized in accordance with a protocol approved by the University of Kentucky Institutional Animal Care and Use Committee.
Bioinformatics analysis of external cohorts
To validate TMA data with external cohorts, the relationship of integrin β4 to tumor type and patient survival was done using the Oncomine microarray database (Oncomine, 
Results
To determine the range of integrin β4 expression in gliomas, immunohistochemistry (IHC)
for the integrin β4 subunit was performed on a set of glioma TMA sections that included 104 cases (see Materials and Methods). We found that integrin β4 expression was uniformly weak in nonneoplastic control tissues as measured by IHC, but that there was a greater range of staining intensities in grade II-IV gliomas (Figures 1A-B ). The overall mean staining intensity was significantly higher in grade IV GBMs when compared to grade II-III tumors and nonneoplastic controls (P < 0.0001; Figure 1B ). TCGA analysis confirmed this association,
showing elevated ITGB4 mRNA in GBMs compared to grade II and III tumors, though the difference in means was relatively modest (Figure 1C) .
IDH mut has been shown to be a strong favorable prognostic factor in diffusely infiltrative gliomas (24) , and high integrin β4 expression can contribute to cancer invasiveness and aggression (55) . Therefore, we sought to determine if a correlation between these two molecules existed. Interestingly, a strong inverse relationship between IDH mut and integrin β4 expression was observed in our TMA cohort (P < 0.0001; Figure 2A-B) . Likewise, an analysis of TCGA gliomas showed that IDH mut tumors had lower average ITGB4 mRNA levels than did IDH wt tumors (P = < 0.0001; Figure 2C ).
IDH mut causes global hypermethylation and gene suppression (24) . Therefore, we examined CpG sites in the integrin β4 gene (ITGB4) and compared its methylation status in IDH wt versus IDH mut tumors. We identified 6 CpG sites in ITGB4 that are significantly hypermethylated in IDH mut tumors when compared to IDH wt tumors (Figure 3A , Supplemental   Table 1 ). Methylation at each of the 6 sites individually correlates with reduced ITGB4 mRNA ( Figure 3B, Supplemental Table 1 ), and 4 of the sites are in the ITGB4 promoter.
Gliomas that harbor IDH mut along with 1p/19q co-deletion are histologically oligodendrogliomas and have a particularly good prognosis, even when compared to IDH mut astrocytomas lacking this co-deletion (8, 14) . As ITGB4 promotes tumor invasiveness and aggression, we determined whether differential regulation of ITGB4 could contribute to the substantially better prognosis observed in this IDH mut subset. By comparing methylation of CpG islands in the ITGB4 gene between IDH mut , 1p/19q intact and IDH mut , 1p/19q co-deleted tumors, we found that, while methylation was increased in IDH mut , 1p/19q intact astrocytomas relative to IDH wt gliomas, it is even higher (up to 3.7 fold) in the IDH mut , 1p/19q co-deleted subset of tumors ( Figure 4A) . Remarkably, only the IDH mut , 1p/19q co-deleted oligodendrogliomas showed reduced ITGB4 mRNA relative to IDH wt gliomas, not the IDH mut , 1p/19q intact astrocytomas (P < 0.0001; Figure 4B ). Among 20,530 genes analyzed in the TCGA via RNA-Seq, ITGB4 is the 56 th most downregulated gene in IDH mut 1p/19q co-deleted gliomas relative to IDH mut 1p/19q
intact gliomas P=3.2x10 -39 , Supplemental Table 2 ). We also compared integrin β4 IHC between the IDH mut and IDH mut , 1p/19q co-deleted subsets in the TMA. However, we did not detect a significant difference in expression in this cohort (P = 0.60; Figure 4C) ; the TMA cohort was likely underpowered to detect such a difference.
Glioma stem cells (GSCs) represent a subset of cells that contribute to glioma growth and self-renewal, and are believed to promote therapy resistance and evasion of anticancer host immunity (32). Previous studies have demonstrated that integrins can mediate cancer stem-cell properties (52) , and this led us to investigate the relationship between integrin β4 expression and self-renewal in patient-derived, CD133+ IDH wt primary GBM cells. Tumors were sorted for integrin β4 surface expression using FACS, and limiting dilution analysis was used to estimate the stem cell frequency of cells isolated from freshly dissociated GBM xenografts. We found that across multiple specimens, integrin β4-high cells had higher stem cell frequencies than was observed in integrin β4-low cells (Figure 5A-D) . To further investigate the role of integrin β4 in glioma growth, we performed loss-of-function studies in cell lines and in an intracranial patientderived xenograft model of glioblastoma. Efficient knockdown of ITGB4 (Figure 6A-B) in LN18 cells dramatically decreased in vitro glioma growth (P < 0.001; Figure 6C) , and significantly extended the survival of mice engrafted with patient-derived, CD133+ IDH wt primary GBM cells (median survival 24.5 days vs. 33 days ; P = 0.01; Figure 6D -E).
To date, no data on integrin β4 and outcome in gliomas has been published. In our TMA cohort, elevated integrin β4 expression was significantly associated with shorter overall survival among all grade II-IV gliomas (median survival not reached for integrin β4 IHC score <1; 63.5 months for 1-1.9; 18.1 months for 2+, P = 0.0005; Figure 7A ). We also examined the relationship between ITGB4 mRNA expression and patient survival in the TCGA glioma cohort (N = 656), where we found that increasing levels of ITGB4 mRNA correlated with worse overall survival (Figures 7B) . Moreover, in the TCGA glioma cohort, ITGB4 expression quartile was found to be an independent prognostic factor, even when including variables such as IDH mut and 1p/19q co-deletion status ( Table 1) .
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Discussion
Our results demonstrate that integrin β4 is highly expressed in GBMs compared to lower grade gliomas and non-neoplastic brain tissue. We found that elevated integrin β4 expression is an adverse prognostic marker, which is consistent with work done in other cancers showing that integrin β4 overexpression imparts more aggressive behavior (55) . We provide evidence that integrin β4 is enriched in the stem-like subset of glioma cells and that it contributes to glioma growth and self-renewal. We find that integrin β4 expression is inversely correlated with IDH mut status, and that methylation and expression of ITGB4 differ according to 1p/19q co-deletion status. Given the role of integrin β4 in tumor malignancy, these findings to help explain why IDH mut , 1p/19q co-deleted oligodendrogliomas generally are even less aggressive than IDH mut astrocytomas with intact 1p/19q (50, 62) .
Global hypermethylation contributes to tumorigenesis by virtue of its ability to suppress cellular differentiation, yet the effects of generalized hypermethylation can eventually lead to changes that inhibit tumor malignancy (24) . For example, IDH mut is associated with hypermethylation of the MGMT promoter and suppression of MGMT (40) , thereby reducing the ability of the tumor to repair DNA damage caused by alkylating chemotherapeutic agents such as temozolomide (22) . We find that methylation of CpG islands in the ITGB4 promoter is significantly higher in IDH mut tumors with 1p/19q co-deletion, and that this hypermethylation is associated with a concomitant reduction in ITGB4 gene expression. In agreement with these findings, epigenetic regulation of integrin β4 expression through promoter hypermethylation and histone modification has been previously described (35).
Mutations in IDH1 are known to promote global DNA and histone methylation, although the exact genes that are methylated can differ between tumor types (18, 28) . We find that while ITGB4 promoter methylation is generally higher in IDH mut gliomas, this phenomenon is mostly due to the 1p/19q co-deleted subset of IDH mut tumors. At this point, it is unclear what mechanism is responsible for this observation. However, in one study of IDH mut gliomas, MGMT promoter methylation was even higher in 1p/19q co-deleted oligodendrogliomas compared to 1p/19q intact astrocytomas, suggesting that secondary genetic alterations may affect the type and degree of IDH mut -induced methylation (34). Genes such as FGFR2 and TNFRFS1B have been shown to be differentially methylated in 1p/19q co-deleted oligodendrogliomas compared to IDH mut astrocytomas (28). Furthermore, secondary mutations, such as in ATRX and TP53 in 1p/19q intact gliomas, and CIC and FUBP1 in 1p/19q co-deleted gliomas, may also influence which genes are hypermethylated in IDH mut tumors.
Our results provide further evidence for the importance of integrins in the GSC population, as we found that integrin β4 is enriched in CD133+ glioma stem cells and that it contributes to glioma self-renewal. A variety of stem cell populations use integrins to associate with extracellular matrix proteins, a relationship that is important for stem cell homing and niche interaction (10) . The integrin β4 interacts with laminins in the extracellular matrix (55) , and laminin-integrin signaling plays a role in the development of neural stem cells (33). In the neoplastic setting, high expression of integrin α6 is a characteristic of GBM stem cells, and its interaction with laminin α2 in the extracellular matrix mediates stem cell properties like selfrenewal and tumor formation (29, 30). In glioblastoma, the integrins α3, α6 and β1 cooperate with CD151 to regulate stemness and self-renewal (59) . Integrin β4 is also a marker for cancer stem cells in other tumor types, and a recent paper demonstrated that integrin β4 identifies a stem-cell enriched population of partially mesenchymal cells in patients with triple negative breast carcinoma (6) .
In addition to their ability to mediate stem-cell properties, integrins have been shown to contribute to other aspects of glioma biology. Integrin β8 is expressed in gliomas, positively correlates with overexpression of Egfr and Pdgfr-α, and may promote Fak and Erk activity in regions rich in extracellular matrix (49) . The αvβ3 and αvβ5 integrins have been implicated in tumor-induced angiogenesis (16) , which is a common feature of GBMs (15) . The αvβ3 and αvβ5
integrins increase with increasing histologic grade in gliomas, and tumor cells at the periphery of high-grade gliomas have higher αvβ3 expression (4). Attempts to target αvβ3 and αvβ5 in GBM led to multiple clinical trials with cilengitide, a small molecule inhibitor of the αvβ3, αvβ5 and α5β1 integrins (39).
To date, few studies have examined integrin β4 expression in gliomas. However, expression of the integrin β4 has been identified in astrocytomas, oligodendrogliomas, and GBMs, as well as in reactive astrocytes (5, 45, 47) . One study found that the integrin β4 was expressed in a mouse model of GBM, that integrin β4 was present early in tumor development, and that expression was more intense within the neoplastic cells of proliferative centers (48) .
In summary, we demonstrate for the first time that expression of the β4 integrin is specifically decreased in IDH mut , 1p/19q co-deleted oligodendrogliomas, and that high integrin β4 correlates with poor prognosis in glioma patients. Further work is needed to clarify the mechanisms by which IDH mut and 1p/19q co-deletion may alter the expression of cellular adhesion molecules, and to examine the role of integrin α6β4 in gliomagenesis and invasion.
Gaining a deeper understanding of why IDH mut gliomas, especially those with 1p/19q codeletion, are less aggressive than their IDH wt counterparts will not only help develop ways of targeting IDH mut gliomas, but also of making IDH wt tumors behave more like IDH mut tumors.
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